---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050145"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:34:43.853669+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pacira Q3 total rev $179.5M (+6% YoY); GAAP net income $5.4M vs loss; guides FY rev lower, gross margin higher

## Summary
- Total revenues $179.5M, up 6% YoY; EXPAREL $139.9M (volume +9% offset by mix and discounting).
- GAAP net income $5.4M ($0.12/share) vs net loss of $143.5M in Q3 2024, which included $163.2M goodwill impairment.
- Adjusted EBITDA $49.4M vs $54.7M; non-GAAP net income $31.8M ($0.72 diluted) vs $38.2M ($0.79) prior year.
- FY2025 revenue guidance lowered to $725-735M from $730-750M; non-GAAP gross margin raised to 80-82% from 78-80%.
- Repurchased 2.0M shares for $50M; $200M remaining on authorization; exclusive license of AMT-143 (ropivacaine) with $5M upfront.

## SEC filing metadata
- accession: 0001628280-25-050145
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/0001628280-25-050145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000162828025050145/pcrx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050145
- JSON: https://secwatch.observer/filing/0001628280-25-050145.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.